Robust rapid disintegration tablet formulation
A rapidly disintegrating, orally administered tablet or compressed dosage form, comprising ethylcellulose (EC) as a directly compressible binder which enhances tablet robustness as manifested by improved strength, lower friability, lower hygroscopicity and yet, hydrophobic nature notwithstanding, does not retard disintegration, but shortens disintegration time or is disintegration time neutral when co-formulated with disintegrants and other water-soluble excipients such as sugar alcohols.
1 . A rapidly disintegrating, low friable tablet formulation comprising:
a) about 1 to 20% by weight of an ethylcellulose binder,
b) about 2 to 15% by weight of a disintegrant,
wherein the ethylcellulose binder has an ethoxyl content in the range of 44 to 54.9% and 5% solution viscosity in the range of about 3 to 200 cps in a 80:20 toluene:ethanol solvent blend and the disintegrant is selected from the group consisting of cross-linked povidone, sodium cross carmellose (cross-linked sodium carboxymethyl cellulose), sodium starch glycollate, low-substituted hydroxypropyl cellulose, and guar.
2 . The rapidly disintegrating, low friable tablet formulation of claim 1 wherein ethylcellulose binder comprises about 3 to 18% by weight of the tablet formulation.
3 . The rapidly disintegrating, low friable tablet formulation of claim 2 wherein ethylcellulose binder comprises about 5 to 15% by weight of the tablet formulation.
4 . The rapidly disintegrating, low friable tablet formulation of claim 1 wherein ethylcellulose binder has an ethoxyl content lower limit of 49.6%.
5 . The rapidly disintegrating, low friable tablet formulation of claim 1 wherein ethylcellulose binder has an ethoxyl content lower limit of 49.8%.
6 . The rapidly disintegrating, low friable tablet formulation of claim 1 wherein ethylcellulose binder has an ethoxyl content lower limit of 50.0%.
7 . The rapidly disintegrating, low friable tablet formulation of claim 1 wherein ethylcellulose binder has an ethoxyl content upper limit of 53.0%.
8 . The rapidly disintegrating, low friable tablet formulation of claim 1 wherein ethylcellulose binder has an ethoxyl content upper limit of 52.0%.
9 . The rapidly disintegrating, low friable tablet formulation of claim 1 wherein ethylcellulose binder has an ethoxyl content upper limit of 51.0%.
10 . The rapidly disintegrating, low friable tablet formulation of claim 1 wherein ethylcellulose binder has 5% solution viscosity less than 53.0 cps in a 80:20 toluene:ethanol solvent blend.
11 . The rapidly disintegrating, low friable tablet formulation of claim 1 wherein ethylcellulose binder has 5% solution viscosity less than 25 cps in a 80:20 toluene:ethanol solvent blend.
12 . The rapidly disintegrating, low friable tablet formulation of claim 1 wherein ethylcellulose binder has 5% solution viscosity less than 17 cps in a 80:20 toluene:ethanol solvent blend.
13 . The rapidly disintegrating, low friable tablet formulation of claim 1 wherein the disintegrant comprises about 3-12% by weight of the tablet formulation.
14 . The rapidly disintegrating, low friable tablet formulation of claim 1 wherein the disintegrant comprises about 5-10% by weight of the tablet formulation.
15 . The rapidly disintegrating, low friable tablet formulation of claim 1 wherein the rapidly disintegrating, low friable tablet formulation further comprises a filler wherein the filler is selected from the group consisting of sucrose, lactose, dextrose, mannitol, xylitol, sorbitol, lactiol, maltodexrin, isomalt, polydextrose, starch and microcrystalline cellulose.
16 . The rapidly disintegrating, low friable tablet formulation of claim 1 wherein the rapidly disintegrating, low friable tablet formulation further comprises a lubricant wherein the lubricant comprises about 0.1 to 2.5% by weight of the tablet formulation.
17 . The rapidly disintegrating, low friable tablet formulation of claim 16 wherein the lubricant comprises about 0.25 to 2.0% by weight of the tablet formulation.
18 . The rapidly disintegrating, low friable tablet formulation of claim 17 wherein the lubricant comprises about 0.5 to 1.5% by weight of the tablet formulation.
19 . The rapidly disintegrating, low friable tablet formulation of claim 16 wherein the lubricant is selected from the group consisting of metal stearates, such as magnesium and calcium stearate, stearic acid, hydrogenated vegetable oils, polyethylene glycol, amino acid and stearyl fumarate.
20 . The rapidly disintegrating, low friable tablet formulation of claim 1 , wherein the rapidly disintegrating, low friable tablet formulation further comprises a flow aid wherein the flow aid is selected from the group consisting of talc and colloidal silicone dioxide.
21 . The rapidly disintegrating, low friable tablet formulation of claim 1 , wherein the rapidly disintegrating, low friable tablet formulation further comprises an active pharmaceutical ingredient.
22 . The rapidly disintegrating, low friable tablet formulation of claim 1 , wherein the active pharmaceutical ingredient is selected from the group consisting of antacids, anti-inflammatory substances, anti-infectives, psychotropics, antimanics, anti-Parkinson's agents, anti-Alzheimer's agents, stimulants, antihistamines, laxatives, decongestants, nutritional supplements, gastrointestinal sedatives, antidiarrheal preparations, antianginal drugs, antiarrhythmics, antihypertensive drugs, vasoconstrictors and migraine treatments, anticoagulants and anti-thrombotic drugs, analgesics, anti-pyretics, hypnotics, sedatives, antiemetics, anti-nauseants, anticonvulsants, neuromuscular drugs, hyper- and hypoglycemic agents, thyroid and antithyroid preparations, diuretics, antispasmodics, uterine relaxants, mineral and nutritional additives, anti-obesity drugs, anabolic drugs, erythropoietic drugs, antiasthmatics, expectorants, cough suppressants, mucolytics, antiuricemic drugs, topical analgesics, local anesthetics, polypeptide drugs, anti-HIV drugs, anti-diabetic agents, chemotherapeutic and anti-neoplastic drugs.
23 . The rapidly disintegrating, low friable tablet formulation of claim 22 , wherein the active pharmaceutical ingredient is selected from the group consisting of aluminum hydroxide, prednisolone, dexamethasone, aspirin, acetaminophen, ibuprofen, isosorbide dinitrate, nicotinic acid, tetracycline, ampicillin, dexbrompheniramine, chlorpheniramine, albuterol pseudoephedrine, loratadine, theophylline, ascorbic acid, tocopherol, pyridoxine, methoclopramide, magnesium hydroxide, verapamil, procainamide hydrochloride, propranolol, captopril, ergotamine, furazepam, diazepam, lithium carbonate, insulin, furosemide, hydrochlorothiazide, guaiphenesin, dextromethorphan, benzocaine, ondansetron, cetrizine, dimenhydrinate, diphenhydramine, vitamin B12, famotidine, ranitidine, omepazole, rabeprazole, esomeprazole, sildenafil, tadalafil, atorvastatin, simvastatin, valsartan, lorsartan, donepezil, galantamine, rivastigmine, carbidopa, levodopa, sertaline, pramipexole and ropinirole.
24 . A method for producing a rapidly disintegrating, low friable tablet comprising the steps of:
a) obtaining and blending an ethylcellulose binder, a disintegrant, and optionally a filler and a flow aid to produce a mixture;
b) compressing the mixture to form the rapidly disintegrating, low friable tablet.
25 . The method for producing a rapidly disintegrating, low friable tablet of claim 24 , further comprising the step of coprocessing the mixture prior to compressing the mixture to form the rapidly disintegrating, low friable tablet wherein the coprocessing step is selected from the group consisting of co-milling, roller compacting and wet agglomeration.
26 . The method for producing a rapidly disintegrating, low friable tablet of claim 25 , further comprising the step of adding a lubricant to the coprocessed mixture.
27 . The method for producing a rapidly disintegrating, low friable tablet of claim 24 , further comprising the step of adding a lubricant to the mixture.